New ICON Survey Highlights Importance of Combination Therapies in Future Obesity Treatment
The majority of respondents believe the future of obesity therapies lies in trials that are designed to measure more than one outcome.
- The majority of respondents believe the future of obesity therapies lies in trials that are designed to measure more than one outcome.
- There is much overlap between obesity and co-morbidities such as diabetes, steatosis (fatty liver), and cardiovascular disease, and in line with this, most respondents (64%) felt combination therapies would be the primary focus of future research.
- Obesity is a growing health concern worldwide, with at least 2.8 million people dying each year because of the disease1.
- There is more to examine on the implications of obesity as a risk factor across the disease spectrum and how it may impact treatment, drug development and clinical trials for obesity.